Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 18, 2017

Primary Completion Date

February 18, 2018

Study Completion Date

May 18, 2018

Conditions
Hepatitis C Genotype 4
Interventions
DRUG

Combined Therapy SOF and DCV

"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"

Trial Locations (1)

Unknown

Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, Madīnat an Naşr

All Listed Sponsors
collaborator

Egyptian Cure Bank

OTHER

collaborator

Society of Friends of Liver Patients in the Arab World (SLPAW)

UNKNOWN

lead

Yassin Abdelghaffar Charity Center for Liver Disease and Research

OTHER

NCT03080415 - Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir | Biotech Hunter | Biotech Hunter